DB-002

N/A

Report date: 2022/11/16 17:18:55

Base Information

Drug NameDB-002

Drug Alias NameDB-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors +[4]

TargetsProgrammed death-ligand 1Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesDotbio Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesDotbio Pte Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A